HOWL Latest News, Press Relases and Analysis

All

Press Releases

17 days ago - By: Werewolf Therapeutics, Inc.

Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

17 days ago - By: Werewolf Therapeutics, Inc.

Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

19 days ago - By: Benzinga - Mentions: RIGL RDHL VCYT RARE ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

20 days ago - By: Werewolf Therapeutics, Inc.

Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

20 days ago - By: Werewolf Therapeutics, Inc.

Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

3 months ago - By: The Motley Fool

Werewolf Reports No Revenue in Fiscal Q2

24 days ago - By: Zacks Investment Research - Mentions: ALKS INSM

Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake

26 days ago - By: Zacks Investment Research - Mentions: ALKS ANIP AVDL

Alkermes Q3 Earnings and Revenues Beat Estimates, 2025 View Raised

a month ago - By: Zacks Investment Research - Mentions: ALNY ALKS VKTX

Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil

a month ago - By: Zacks Investment Research

Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why

2 months ago - By: Werewolf Therapeutics, Inc.

Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer

2 months ago - By: Werewolf Therapeutics, Inc.

Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer

2 months ago - By: Werewolf Therapeutics, Inc.

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

2 months ago - By: Werewolf Therapeutics, Inc.

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

2 months ago - By: Benzinga - Mentions: PBM AGIO MTNB HSDT ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

3 months ago - By: Zacks Investment Research

Werewolf Therapeutics, Inc. (HOWL) Just Flashed Golden Cross Signal: Do You Buy?

3 months ago - By: Werewolf Therapeutics, Inc.

Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference

3 months ago - By: Werewolf Therapeutics, Inc.

Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

3 months ago - By: Werewolf Therapeutics, Inc.

Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

3 months ago - By: Zacks Investment Research - Mentions: XOMA

XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates

3 months ago - By: Zacks Investment Research - Mentions: XAIR

Beyond Air, Inc. (XAIR) Reports Q1 Loss, Lags Revenue Estimates

4 months ago - By: Zacks Investment Research - Mentions: CRMD

CorMedix (CRMD) Surpasses Q2 Earnings and Revenue Estimates

4 months ago - By: Yahoo Finance

ReAlta Life Sciences Appoints Ellen Lubman as Chief Business Officer

5 months ago - By: Werewolf Therapeutics, Inc.

Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit

5 months ago - By: Werewolf Therapeutics, Inc.

Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit

5 months ago - By: Werewolf Therapeutics, Inc.

Werewolf Therapeutics to Participate in the BIO International Convention

6 months ago - By: Yahoo Finance - Mentions: NPCE IVVD ENPH KROS ...

H.C. Wainwright Initiates Coverage of NeuroPace (NPCE) With Buy Rating

6 months ago - By: Yahoo Finance - Mentions: IVVD NPCE THC KROS ...